Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Phio Pharmaceuticals Corp. PHIO
$3.56
-$0.38 (-10.55%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
6003194.00000000
-
week52high
12.27
-
week52low
3.11
-
Revenue
0
-
P/E TTM
0
-
Beta
1.53079500
-
EPS
-11.65000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 14 июн 2021 г. |
| HC Wainwright & Co. | Buy | 25 ноя 2020 г. | |
| HC Wainwright & Co. | Buy | 05 авг 2020 г. | |
| H.C. Wainwright | Buy | Buy | 09 июл 2018 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Bitterman Robert J | A | 74541 | 2000 | 14 дек 2022 г. |
| Bitterman Robert J | A | 72541 | 2000 | 07 дек 2022 г. |
| Bitterman Robert J | A | 70541 | 2000 | 05 дек 2022 г. |
| Ferrara Robert L | A | 30000 | 5000 | 02 дек 2022 г. |
| Bitterman Robert J | A | 68541 | 215 | 29 ноя 2022 г. |
| Bitterman Robert J | A | 68326 | 2500 | 25 ноя 2022 г. |
| Ferrara Robert L | A | 25000 | 2000 | 23 ноя 2022 г. |
| Bitterman Robert J | A | 1 | 1 | 16 ноя 2022 г. |
| Bitterman Robert J | A | 65826 | 40000 | 01 окт 2022 г. |
| BRADFORD PATRICIA A | A | 20000 | 20000 | 09 авг 2022 г. |
Новостная лента
Why Is PHIO Stock Down 20% Today?
InvestorPlace
18 апр 2023 г. в 14:24
It's been a big day for investors in Phio Pharmaceuticals (NASDAQ: PHIO ), unfortunately on the downside. This afternoon, PHIO stock has declined nearly 20% on a couple of key announcements.
Phio Pharmaceuticals Corp. (PHIO) Reports Q3 Loss, Lags Revenue Estimates
Zacks Investment Research
10 ноя 2022 г. в 19:33
Phio Pharmaceuticals Corp. (PHIO) delivered earnings and revenue surprises of -172.22% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
What Makes Phio Pharmaceuticals Corp. (PHIO) a New Buy Stock
Zacks Investment Research
25 окт 2022 г. в 13:32
Phio Pharmaceuticals Corp. (PHIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.